Discovery may lead to new drugs to curb obesity, type 2 diabetes

October 11, 2012

(Medical Xpress)—An international study led by a researcher from The University of Western Australia for the Western Australian Institute for Medical Research (WAIMR) has produced exciting results that may lead to new drugs to treat obesity and reduce the incidence of Type 2 diabetes.

UWA Assistant Professor Vance Matthews led researchers in Melbourne, Texas and Japan to explore the effects of a protein on the surface of on conditions such as Type 2 diabetes and obesity.

Their results have appeared in the high-ranking immunology journal Immunology and Cell Biology, published by the .

Assistant Professor Matthews said the research was particularly important because had increased by 75% in the past 25 years, including an alarming increase in overweight and obese children. Insulin resistance correlated directly with obesity and could result in Type 2 diabetes, in which occurred in metabolically active body tissues.

"While my research looks at the growing problems of obesity and type 2 diabetes and how the inflammatory pathways are activated in our bodies, our discoveries also have far-reaching consequences for other diseases that involve inflammation," Assistant Professor Matthews said.

The study established that many parameters of the metabolic syndrome such as obesity and insulin resistance were significantly correlated with high levels of the metalloproteinase known as ADAM28 in .

The group explored interactions between the protein TNF-alpha – which is produced by numerous inflammatory cell types – and the metalloproteinase ADAM28. TNF-alpha is a well-known cytokine that promotes and increases the risk of Type 2 diabetes.

The study highlighted that the metalloproteinase ADAM28 may increase the release of TNF-alpha protein from the cell surface, and this effect may promote inflammation.

"Our project is very significant because it demonstrates for the first time the importance of ADAM28 in the metabolic syndrome, and further supports that metalloproteinase inhibition is a potential therapeutic target for anti-obesity agents," Assistant Professor Matthews said.

"This means that further down the track, drugs may become available to treat obesity, therefore reducing the incidence of type 2 diabetes."

Explore further: Researchers identify key regulator of inflammatory response

Related Stories

Researchers identify key regulator of inflammatory response

April 12, 2012
(Medical Xpress) -- Researchers at Boston University School of Medicine (BUSM) have identified a gene that plays a key role in regulating inflammatory response and homeostasis. These findings could help lead to the development ...

New inflammation hormone link may pave way to study new drugs for Type 2 diabetes

May 15, 2012
A new link between obesity and type 2 diabetes found in mice could open the door to exploring new potential drug treatments for diabetes, University of Michigan Health System research has found.

New tactic for controlling blood sugar in diabetes contradicts current view of the disease

September 4, 2011
Increased low-grade inflammation in the body resulting from obesity is widely viewed as contributing to type 2 diabetes. Going against this long-held belief, researchers from Children's Hospital Boston report that two proteins ...

Recommended for you

Genetic immune deficiency could hold key to severe childhood infections

July 18, 2017
A gene mutation making young children extremely vulnerable to common viruses may represent a new type of immunodeficiency, according to a University of Queensland researcher.

What are the best ways to diagnose and manage asthma?

July 18, 2017
What are the best ways to diagnose and manage asthma in adults? This can be tricky because asthma can stem from several causes and treatment often depends on what is triggering the asthma.

Large multi-ethnic study identifies many new genetic markers for lupus

July 17, 2017
Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus.

Study finds molecular explanation for struggles of obese asthmatics

July 17, 2017
A large, bouquet-shaped molecule called surfactant protein A, or SP-A, may explain why obese asthma patients have harder-to-treat symptoms than their lean and overweight counterparts, according to a new study led by scientists ...

Team identifies potential cause for lupus

July 14, 2017
Leading rheumatologist and Feinstein Institute for Medical Research Professor Betty Diamond, MD, may have identified a protein as a cause for the adverse reaction of the immune system in patients suffering from lupus. A better ...

Immunosuppression underlies resistance to anti-angiogenic therapy

July 14, 2017
A Massachusetts General Hospital (MGH) research team has identified a novel mechanism behind resistance to angiogenesis inhibitors - drugs that fight cancer by suppressing the formation of new blood vessels. In their report ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.